|
|
Volumn 10, Issue 11, 2011, Pages 809-810
|
|
The depression market
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AGOMELATINE;
AMITRIPTYLINE;
ANTIDEPRESSANT AGENT;
ARIPIPRAZOLE;
ATYPICAL ANTIPSYCHOTIC AGENT;
CITALOPRAM;
DULOXETINE;
EDIVOXETINE;
F 2695;
FLUOXETINE;
IMIPRAMINE;
LISDEXAMFETAMINE;
LU AA 21004;
MECAMYLAMINE;
MILNACIPRAN;
OPC 34712;
PAROXETINE;
QUETIAPINE;
SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;
SEROTONIN UPTAKE INHIBITOR;
SERTRALINE;
TC 5214;
TRICYCLIC ANTIDEPRESSANT AGENT;
UNCLASSIFIED DRUG;
VENLAFAXINE;
VILAZODONE;
ADJUVANT THERAPY;
ARTICLE;
BODY WEIGHT;
CARDIOVASCULAR DISEASE;
DEPRESSION;
DRUG ACTIVITY;
DRUG APPROVAL;
DRUG MECHANISM;
DRUG PROTEIN BINDING;
DRUG RESPONSE;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG TREATMENT FAILURE;
DRUG WITHDRAWAL;
DYSKINESIA;
ELECTROCONVULSIVE THERAPY;
HUMAN;
INSOMNIA;
MAJOR DEPRESSION;
METABOLIC DISORDER;
NAUSEA;
PRIORITY JOURNAL;
SEXUAL DYSFUNCTION;
SEXUAL FUNCTION;
SIDE EFFECT;
THERAPY RESISTANCE;
UNSPECIFIED SIDE EFFECT;
WEIGHT GAIN;
ACETAMIDES;
ANTIDEPRESSIVE AGENTS;
CLINICAL TRIALS AS TOPIC;
DEPRESSIVE DISORDER;
DRUG DISCOVERY;
HUMANS;
MELATONIN;
|
|
EID: 80155142476
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3585 Document Type: Article |
|
Times cited : (23)
|
|
References (5)
|
